Profile data is unavailable for this security.
About the company
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
- Revenue in HKD (TTM)274.85m
- Net income in HKD-231.63m
- Incorporated2018
- Employees429.00
- LocationAlphamab OncologyNo. 175Fangzhou Road, Suzhou Industrial ParkSuzhou 215125ChinaCHN
- Phone+86 51 262850800
- Websitehttps://www.alphamabonc.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocytogen Pharmaceuticals Beijng Co Ltd | 859.97m | -261.91m | 2.40bn | 1.04k | -- | 3.02 | -- | 2.79 | -0.6576 | -0.6576 | 2.16 | 1.99 | 0.3109 | 23.64 | 5.36 | 806,728.50 | -9.47 | -- | -12.44 | -- | 71.97 | -- | -30.46 | -- | 1.33 | -4.18 | 0.436 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
| CStone Pharmaceuticals | 490.40m | -152.87m | 2.56bn | 164.00 | -- | 5.09 | -- | 5.21 | -0.12 | -0.12 | 0.3847 | 0.3912 | 0.2861 | 1.33 | 2.50 | 2,132,195.00 | -8.92 | -54.76 | -16.99 | -81.68 | 70.73 | -- | -31.17 | -301.62 | 1.45 | -- | 0.4171 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 404.97k | -402.17m | 2.74bn | 150.00 | -- | 4.25 | -- | 6,772.28 | -1.12 | -1.12 | 0.0011 | 1.72 | -- | -- | -- | 2,792.90 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
| Abbisko Cayman Ltd | 534.17m | -17.40m | 3.15bn | 275.00 | -- | 1.41 | 886.04 | 5.89 | -0.0295 | -0.0295 | 0.8225 | 3.27 | 0.2159 | -- | 65.75 | 2,070,417.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
| CARsgen Therapeutics Holdings Ltd | 6.81m | -746.44m | 4.13bn | 477.00 | -- | 2.58 | -- | 605.92 | -1.34 | -1.34 | 0.0122 | 2.79 | 0.0027 | -- | 0.302 | 13,198.43 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Alphamab Oncology | 274.85m | -231.63m | 4.41bn | 429.00 | -- | 2.53 | -- | 16.04 | -0.2406 | -0.2406 | 0.2855 | 1.81 | 0.1145 | 0.8256 | 13.94 | 631,848.10 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
| Laekna Inc | 0.00 | -317.46m | 5.19bn | 92.00 | -- | 7.14 | -- | -- | -0.8909 | -0.8909 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| Lepu Biopharma Co Ltd | 220.30m | -78.01m | 5.22bn | 491.00 | -- | 5.31 | 383.59 | 23.68 | -0.0462 | -0.0462 | 0.1323 | 0.5744 | 0.0847 | 1.86 | 1.53 | 513,514.70 | -3.53 | -- | -5.72 | -- | 78.76 | -- | -41.62 | -- | 0.7322 | -2.71 | 0.4621 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Alphamab Oncology's reporting currency: Hong Kong Dollar HKD
4.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 23.56m | 2.44% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 7.17m | 0.74% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 3.57m | 0.37% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 2.56m | 0.27% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 743.00k | 0.08% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 622.00k | 0.06% |
| China Asset Management (Hong Kong) Ltd.as of 30 Sep 2024 | 565.13k | 0.06% |
| Vanguard Fiduciary Trust Co.as of 31 Aug 2024 | 531.91k | 0.06% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 455.00k | 0.05% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 282.00k | 0.03% |
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
